Amarin Corporation PLC (NASDAQ:AMRN) Position Raised by Perkins Capital Management Inc

Judith Bessette
Agosto 13, 2017

08/10/2015 - Amarin Corporation PLC had its "perform" rating reiterated by analysts at Oppenheimer. Three analysts have issued estimates for Amarin Corporation PLC's earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Institutional owners keep 38.20% hold Insiders owns 0.40% shares of the company. Point72 Asset Management L.P. acquired a new position in shares of Amarin Corporation PLC during the first quarter worth $960,000. For the next fiscal year, analysts expect that the business will post earnings of $0.01 per share, with EPS estimates ranging from ($0.11) to $0.24. Tower Research Capital Ltd Liability Corp (Trc) holds 2,373 shares.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.01. During the same period previous year, the firm earned ($0.07) EPS. Morgan Stanley stated it has 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN).

Amarin Corporation plc (AMRN) reported sales (ttm) of 139.2 Million, whereas, 4 number of analysts estimated the mean sale of 45.17 million. Jefferies Group LLC increased their target price on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the stock a "buy" rating in a research note on Friday, June 30th. Zacks Investment Research downgraded Amarin Corporation PLC from a "buy" rating to a "hold" rating in a research report on Monday, August 7th. Cantor Fitzgerald maintained it with "Buy" rating and $500 target in Monday, June 12 report. Zacks Investment Research raised shares of Amarin Corporation PLC from a "sell" rating to a "hold" rating in a research note on Monday, July 3rd. Jefferies Group LLC reissued a buy rating and issued a $5.00 price target on shares of Amarin Corporation PLC in a report on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of "Buy" and a consensus price target of $7.35.

Amarin Corporation PLC (NASDAQ:AMRN) traded down 0.86% during midday trading on Wednesday, hitting $3.47.

Nitish Kumar likely to be NDA convenor
He added that this was not personal fight against Nitish Kumar but a fight of principles and to save democracy and brotherhood. Summary: "It is Kumar who changed the mandate given by 11 crore people in favour of Mahagathbandhan (Grand Alliance)".

Amarin Corporation plc (AMRN) changed 2.88 million shares at hands on August 11, 2017 versus to the average volume of 2.45 million shares. Amarin Corporation PLC has a 52-week low of 2.56 and a 52-week high of 4.47. The stock's 50-day moving average price is $3.87 and its 200-day moving average price is $3.31. It has a market cap of $883.17 Million. The stock was sold at an average price of $4.00, for a total transaction of $1,231,644.00.

The stock decreased 4.57% or $0.16 during the last trading session, reaching $3.34. H.C. Wainwright maintained the shares of AMRN in report on Thursday, August 3 with "Buy" rating. Quantitative Investment Management LLC boosted its stake in Amarin Corporation PLC by 105.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company's stock valued at $460,000 after buying an additional 2,050 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Amarin Corporation PLC by 1.4% in the first quarter. Wells Fargo & Company MN boosted its stake in shares of Amarin Corporation PLC by 4.8% in the first quarter. Finally, California Public Employees Retirement System boosted its position in Amarin Corporation PLC by 13.3% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company's stock valued at $1,266,000 after buying an additional 3,413 shares in the last quarter. The fund owned 41,500 shares of the biopharmaceutical company's stock after buying an additional 7,000 shares during the period.

TRADEMARK VIOLATION NOTICE: This news story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and global trademark & copyright legislation.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL